Fixed-duration Ibrutinib Plus Venetoclax May Benefit Patients with High-risk Chronic Lymphocytic Leukemia
PHILADELPHIA – First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic...